Cryptococcal therapies and drug targets: the old, the new and the promising
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Half a century after the introduction of Amphotericin B the management of cryptococcosis remains unsatisfactory. The disease, caused primarily by the two fungal species Cryptococcus neoformans and Cryptococcus gattii, remains responsible for considerable morbidity and mortality despite standard medical care. Current therapeutic options are limited to Amphotericin B, azoles and 5-flucytosine. However, this organism has numerous well-characterized virulence mechanisms that are amenable to pharmacological interference and are thus potential therapeutic targets. Here, we discuss existing approved antifungal drugs, resistance mechanisms to these drugs and non-standard antifungal drugs that have potential in treatment of cryptococcosis, including immunomodulatory strategies that synergize with antifungal drugs, such as cytokine administration or monoclonal antibodies. Finally, we summarize attempts to target well-described virulence factors of Cryptococcus, the capsule or fungal melanin. This review emphasizes the pressing need for new therapeutic alternatives for cryptococcosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Rodrigues, M. L., Nakayasu, E. S., Oliveira, D. L., Nimrichter, L., Nosanchuk, J. D., Almeida, I. C., & Casadevall, A. (2008) · Eukaryotic Cell · doi:10.1128/ec.00370-07 · Cited by 558
Self-citationUrease as a Virulence Factor in Experimental Cryptococcosis
Cox, G. M., Mukherjee, J., Cole, G. T., Casadevall, A., & Perfect, J. R. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.443-448.2000 · Cited by 522
Self-citationJarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367 · cited 2×
“© 2016 John Wiley & Sons Ltd, Cellular Microbiology, 18, 792–799 IFN-γ Interferon-γ is a key cytokine in cryptococcosis such that in human patients a strong IFN-γ response indicates a good prognosis (Jarvis et al., 2012; Jarvis et al., 2014).”
BackgroundMelanin-lacking mutants of Cryptococcus neoformans and their virulence for mice
Kwon-Chung, K. J., Polacheck, I., & Popkin, T. J. (1982) · Journal of Bacteriology · doi:10.1128/jb.150.3.1414-1421.1982 · Cited by 327 · cited 1×
“Their use in clinical trials phase I (Larsen et al., 2005) was promising.”
BackgroundHarnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-A., Rivera, J., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1437 · Cited by 298 · cited 1×
“The lack of Ab response can be overcome by use of polysaccharide–conjugate vaccines, which elicit strong antibody responses and allowed the isolation of several anti-capsule mAb from mice (Casadevall et al., 1992; Casadevall et al., 1998; Shapiro et al., 2002).”
BackgroundSelf-citationJarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290 · cited 1×
“High-throughput screens generated at least two new classes of compounds with anticryptococcal activity in vitro: hydroxyaldimines or Schiff bases, (Magalhães et al., 2013) and aminiothiazioles (Khalil et al., 2015).”
Larsen, R. A., Pappas, P. G., Perfect, J., Aberg, J. A., Casadevall, A., Cloud, G. A., James, R., Filler, S., & Dismukes, W. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.952-958.2005 · Cited by 236
Self-citationZhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205 · cited 8×
“Severe toxicity of AmpB was a significant problem pushing the development of novel liposomal formulations which succeed in improving AmpB safety.”
BackgroundInfluentialRecombinant Interferon‐γ1b as Adjunctive Therapy for AIDS‐Related Acute Cryptococcal Meningitis
Pappas, P. G., Bustamante, B., Ticona, E., Hamill, R. J., Johnson, P. C., Reboli, A., Aberg, J., Hasbun, R., & Hsu, H. H. (2004) · The Journal of Infectious Diseases · doi:10.1086/420829 · Cited by 202 · cited 1×
“The first found a trend towards better clinical outcome and earlier CNS sterilization but no differences in survival (Pappas et al., 2004).”
ResultLoss of cell wall alpha(1‐3) glucan affects Cryptococcus neoformans from ultrastructure to virulence
Reese, A. J., Yoneda, A., Breger, J. A., Beauvais, A., Liu, H., Griffith, C. L., Bose, I., Kim, M., Skau, C., Yang, S., et al. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05551.x · Cited by 183
Rhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183 · cited 1×
“However results from clinical trials phase I/II were encouraging enough to proceed to phase III as adjunctive to combination therapy of AmpB and fluconazole (Reese et al., 2007; Rhein et al., 2016).”
BackgroundMaligie, M. A., & Selitrennikoff, C. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2851-2856.2005 · Cited by 178
Vu, K., Tham, R., Uhrig, J. P., Thompson, G. R., Na Pombejra, S., Jamklang, M., Bautos, J. M., & Gelli, A. (2014) · mBio · doi:10.1128/mbio.01101-14 · Cited by 159
Pfaller, M. A., Messer, S. A., Georgopapadakou, N., Martell, L. A., Besterman, J. M., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00618-09 · Cited by 143
Levitz, S. M., Harrison, T. S., Tabuni, A., & Liu, X. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119688 · Cited by 121 · cited 1×
“Melanin and laccase Melanin is a pigment synthesized by the enzyme laccase that is important for virulence for many pathogenic microbes and Cryptococcus spp. in particular (KwonChung et al., 1982; Liu and Nizet, 2009).”
BackgroundGilbert, N. M., Donlin, M. J., Gerik, K. J., Specht, C. A., Djordjevic, J. T., Wilson, C. F., Sorrell, T. C., & Lodge, J. K. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07119.x · Cited by 113 · cited 1×
“Chloroquine antifungal effects range from inhibition of Cryptococcus growth (Harrison et al., 2000; Perfectet al., 2010) to facilitating an increase in yeast killing by macrophages (Perfect and Cox, 1999; Khan et al., 2005).”
BackgroundSionov, E., Chang, Y. C., & Kwon-Chung, K. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00694-13 · Cited by 112 · cited 1×
“For the azoles most if not all isolates include a subpopulation intrinsically resistant to azoles (Bratton et al., 2012; Sionov et al., 2013; Saijo et al., 2014).”
BackgroundMcClelland, E. E., Nicola, A. M., Prados-Rosales, R., & Casadevall, A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38322 · Cited by 101
Self-citationMaruvada, R., Zhu, L., Pearce, D., Zheng, Y., Perfect, J., Kwon-Chung, K. J., & Kim, K. S. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2012.01819.x · Cited by 75 · cited 2×
“Later, other cryptococcal molecules were associated with CNS dissemination: phospholipase B1, which interacts with host cell Rac1 (Maruvada et al., 2012); the hyaluronic acid-like product of Csp1 gene, which interacts with CD44 in endothelium (Kim et al., 2012) andMpr1metalloprotease (Vu et al.,…”
BackgroundMoney, N. P., Caesar-TonThat, T.-C., Frederick, B., & Henson, J. M. (1998) · Fungal Genetics and Biology · doi:10.1006/fgbi.1998.1052 · Cited by 56
Kim, J.-C., Crary, B., Chang, Y. C., Kwon-Chung, K. J., & Kim, K. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.389676 · Cited by 47 · cited 1×
“Administration of unmethylated CpG nucleotides (Kinjo et al., 2007) or amimic of microbial RNA, poly-IC, (Sionov et al., 2015) delayed mouse death upon Cryptococcus infection.”
BackgroundIs there a role for statins in fungal infections?
Bergman, P. W., & Björkhem-Bergman, L. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.856755 · Cited by 12 · cited 2×
“However a meta analysis of five retrospective studies found no positive effects for the use of statins during fungal infection (Bergman and Björkhem-Bergman, 2013).”
Background
Cited by
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases
Kak, G., Raza, M., & Tiwari, B. K. (2018) · Biomolecular Concepts · doi:10.1515/bmc-2018-0007 · Cited by 617
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
Self-citationMechanisms of Pulmonary Escape and Dissemination by Cryptococcus neoformans
Denham, S., & Brown, J. (2018) · Journal of Fungi · doi:10.3390/jof4010025 · Cited by 67
“neoformans, melanin pigment is exported to the cell wall [105], where it provides protection against ultraviolet radiation and oxidative damage [106,107].”
BackgroundSynergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
“To date, there are only four classes of antifungals, which primarily target the fungal cell envelope (cell wall and plasma membrane) (Coelho and Casadevall, 2016; Odds et al., 2003; Pianalto and Alspaugh, 2016; Scorzoni et al., 2017).”
Background
Metadata
- Authors
- Coelho, C., & Casadevall, A.
- Venue
- Cellular Microbiology
- Publisher
- Wiley
- Published
- 2016-04-08
- Volume
- 18
- Issue
- 6
- Pages
- 792-799
- ISSN
- 1462-5814 (ISSN-L)
- OpenAlex
- W2301515547
- Cited by
- 95
- References
- 24
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.